Company news
Pharvaris N.v. (NASDAQ:PHVS) news
Every Pharvaris N.v. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
September 8, 2026
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
September 3, 2026
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated T...
July 22, 2026
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
July 6, 2026
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
June 15, 2026
Pharvaris Announces Annual General Meeting of Shareholders
June 11, 2026
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
May 29, 2026
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purch...
May 11, 2026
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
May 8, 2026
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
April 20, 2026
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
April 2, 2026
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Alle...
March 11, 2026
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angi...
March 2, 2026
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
February 10, 2026
Pharvaris Outlines 2026 Strategic Priorities
January 12, 2026
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HA...
December 3, 2025
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
November 12, 2025
Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting
November 10, 2025
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
October 23, 2025
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Und...
July 24, 2025
Pharvaris Announces Proposed Public Offering of Ordinary Shares
July 22, 2025
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
July 22, 2025
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
July 10, 2025
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National ...
June 27, 2025
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the E...
June 16, 2025
Pharvaris Announces Annual Meeting of Shareholders
June 10, 2025
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
June 2, 2025
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
May 19, 2025
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
May 12, 2025
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
April 7, 2025
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
April 1, 2025
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
March 3, 2025
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint C...
March 3, 2025
Pharvaris Outlines 2025 Strategic Priorities
January 13, 2025
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
November 13, 2024
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
November 12, 2024
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
October 24, 2024
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
October 16, 2024
Pharvaris to Host Virtual Investor Event on October 23, 2024
October 15, 2024
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
October 3, 2024
Pharvaris Presents Data at the Bradykinin Symposium 2024
September 5, 2024
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symp...
September 5, 2024
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
September 5, 2024
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
August 28, 2024
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
June 4, 2024